News | November 10, 2025
Bristol Myers Squibb prices €5 billion senior unsecured notes offering
The offering is expected to close on November 10, 2025, subject to customary closing conditions
The offering is expected to close on November 10, 2025, subject to customary closing conditions
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
NewCo’s pipeline includes five investigational medicines
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Subscribe To Our Newsletter & Stay Updated
